<DOC>
	<DOC>NCT01687478</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.</brief_summary>
	<brief_title>A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Have single or recurrent unipolar major depressive disorder (MDD) without psychotic features by Diagnostic and Statistical Manual of Mental Disorders, Fourth EditionText Revision (DSMIVTR) clinical assessment Have a total score ≥22 on the 17item Hamilton Depression Rating Scale (HAMD17) at screening and randomization Have treatmentresistant depression (TRD), defined as having failed to achieve a satisfactory antidepressant response, in the opinion of the investigator, to separate treatment courses of at least 2 different antidepressants, other than fluoxetine, of adequate dosage and duration (≥6 weeks) within the current major depressive episode Have a diagnosis of Parkinson's disease or a related disorder Have a current or lifetime diagnosis of any of the following conditions, according to DSMIVTR criteria: Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder; Delusional Disorder; Psychotic Disorder Not Otherwise Specified; Bipolar Disorder I or II; Delirium of any type; Dementia of any type; Amnestic Disorder; any SubstanceInduced Disorder; or any Psychotic Disorder due to a General Medical Condition Have a current diagnosis of postpartum depression or MDD with a seasonal pattern as defined in the DSMIVTR Have paranoid, schizoid, schizotypal, antisocial, or borderline personality disorder (Axis II) as a comorbid or primary diagnosis, based on DSMIVTR criteria Have DSMIVTR substance dependence/abuse or are not willing to avoid use of the substance (not including dependence on nicotine or caffeine) within 30 days of screening Are actively suicidal in the judgment of the investigator Have uncorrected narrowangle glaucoma Have had one or more seizures without a clear and resolved etiology Have leukopenia Have any acute, serious, or unstable medical conditions Have an increased serum prolactin concentration at screening Have a ratecorrected cardiac QT interval, calculated using Bazett's formula (QTc Bazett's [QTcB]), on Electrocardiogram (ECG) &gt;450 milliseconds (male) or &gt;470 milliseconds (female) at screening Have a history of allergic reaction to olanzapine, fluoxetine, or olanzapine in combination with fluoxetine Have had treatment with olanzapine, fluoxetine, or olanzapine in combination with fluoxetine withdrawn due to clinically significant and/or intolerable adverse effects within 6 months of screening Have received treatment with remoxipride within 6 months of randomization Have received treatment with depot antipsychotics within one dosing interval before randomization Have received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) treatment within the current MDD episode, or has a history of failure to respond to adequate treatment courses of ECT or VNS, or is expected to require ECT or VNS at any time during the study Have received previous treatment with clozapine Have received treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of screening, or are expected to need MAOI treatment at any time during the study or up until 5 weeks after study discontinuation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>